Renaissance Capital logo

Cirius Therapeutics Filed, US Offering, Nasdaq: CSTX

Phase 2 biotech developing therapies for NASH.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. Our lead product candidate, MSDC-0602K, is a novel, once-daily, oral small molecule being developed to treat NASH with fibrosis. MSDC-0602K selectively modulates the MPC, which mediates at the cellular level the effects of overnutrition, a major cause of NASH and other metabolic disorders. We are conducting a Phase 2b clinical trial, the EMMINENCE trial, of MSDC-0602K, which we have fully enrolled with 402 patients diagnosed with NASH with fibrosis.
more less
IPO News for Cirius Therapeutics
more
IPO Data
IPO File Date 01/11/2019
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $86
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $86
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters San Diego, CA
Founded 2015
Employees 11
Website www.ciriustx.com